BACKGROUND: Add-on repetitive transcranial magnetic stimulation (rTMS) is effective in treating medication-resistant depression (MRD), but little is known about the rTMS antidepressant mechanism and pathophysiology underlying MRD. METHODS: Twenty MRD patients received 2 weeks of navigated add-on rTMS to the left dorsolateral prefrontal cortex (DLPFC). Treatment response was defined as a ≥50% decrease in HDRS after treatment. Cerebral glucose metabolism was measured from all MRD patients twice, before and 3 months after rTMS, and from 20 healthy controls once at baseline. RESULTS: At baseline, MRD subjects presented significant hypometabolism at the bilateral DLPFC and anterior cingulum, as well as hypermetabolism at several limbic and subcortical regions compared to the controls. Higher metabolism at the medial PFC and rostral anterior cingulum, and lower metabolism at the limbic structures, including the left parahippocampus and fusiform gyrus, predicted a response to rTMS. After successful rTMS treatment, the abnormally elevated metabolism in the left middle temporal cortex and fusiform gyrus decreased significantly, suggesting a reversal of metabolic imbalances. However, the overall metabolic pattern was still abnormal, even after their depression was under control. In contrast, the non-responders showed a worsening pattern of increased metabolism in the bilateral temporal cortex and fusiform gyrus. CONCLUSIONS: The antidepressant mechanism of add-on rTMS may be reflected as suppression of hyperactivity in the left temporal cortex and fusiform gyrus, perhaps through enhancing the function of the medial prefrontal cortex and anterior cingulum. The limbic-cortical dysregulation of glucose metabolism might be a trait of an underlying mechanism of MRD.
BACKGROUND: Add-on repetitive transcranial magnetic stimulation (rTMS) is effective in treating medication-resistant depression (MRD), but little is known about the rTMS antidepressant mechanism and pathophysiology underlying MRD. METHODS: Twenty MRD patients received 2 weeks of navigated add-on rTMS to the left dorsolateral prefrontal cortex (DLPFC). Treatment response was defined as a ≥50% decrease in HDRS after treatment. Cerebral glucose metabolism was measured from all MRD patients twice, before and 3 months after rTMS, and from 20 healthy controls once at baseline. RESULTS: At baseline, MRD subjects presented significant hypometabolism at the bilateral DLPFC and anterior cingulum, as well as hypermetabolism at several limbic and subcortical regions compared to the controls. Higher metabolism at the medial PFC and rostral anterior cingulum, and lower metabolism at the limbic structures, including the left parahippocampus and fusiform gyrus, predicted a response to rTMS. After successful rTMS treatment, the abnormally elevated metabolism in the left middle temporal cortex and fusiform gyrus decreased significantly, suggesting a reversal of metabolic imbalances. However, the overall metabolic pattern was still abnormal, even after their depression was under control. In contrast, the non-responders showed a worsening pattern of increased metabolism in the bilateral temporal cortex and fusiform gyrus. CONCLUSIONS: The antidepressant mechanism of add-on rTMS may be reflected as suppression of hyperactivity in the left temporal cortex and fusiform gyrus, perhaps through enhancing the function of the medial prefrontal cortex and anterior cingulum. The limbic-cortical dysregulation of glucose metabolism might be a trait of an underlying mechanism of MRD.
Authors: Aaron D Boes; Brandt D Uitermarkt; Fatimah M Albazron; Martin J Lan; Conor Liston; Alvaro Pascual-Leone; Marc J Dubin; Michael D Fox Journal: Brain Stimul Date: 2018-01-31 Impact factor: 8.955
Authors: Thiago M Fidalgo; J Leon Morales-Quezada; Guilherme S C Muzy; Noelle M Chiavetta; Mariana E Mendonca; Marcus V B Santana; Oscar F Goncalves; Andre R Brunoni; Felipe Fregni Journal: J ECT Date: 2014-03 Impact factor: 3.635
Authors: Paulo J C Suen; Sarah Doll; Marcelo C Batistuzzo; Geraldo Busatto; Lais B Razza; Frank Padberg; Eva Mezger; Lucia Bulubas; Daniel Keeser; Zhi-De Deng; Andre R Brunoni Journal: Eur Arch Psychiatry Clin Neurosci Date: 2020-04-11 Impact factor: 5.270
Authors: Tim V Salomons; Katharine Dunlop; Sidney H Kennedy; Alastair Flint; Joseph Geraci; Peter Giacobbe; Jonathan Downar Journal: Neuropsychopharmacology Date: 2013-09-13 Impact factor: 7.853
Authors: Maria Concetta Pellicciari; Susanna Cordone; Cristina Marzano; Stefano Bignotti; Anna Gazzoli; Carlo Miniussi; Luigi De Gennaro Journal: Front Hum Neurosci Date: 2013-08-02 Impact factor: 3.169